Many of the biggest breakthroughs in the way pediatric blood disorders and cancers are treated can be traced back to research performed at Dana-Farber Cancer Institute and Boston Children’s Hospital. We published the first experience with double autologous peripheral blood stem cell transplant for high-risk neuroblastoma. We are a leader in clinical trials for Ewing sarcoma; five-year event-free survival rates are now at about 70 percent. Today, we are pioneering the use of interventional radiology for the surgical removal of pediatric tumors, and we are one of only a few centers nationally to offer I-131 MIBG therapy for children with relapsed neuroblastoma. Continue reading to learn about our current clinical trials for children with solid tumors.
If you need help determining whether your child might be eligible for one of our clinical trials, email us at email@example.com. We can help you navigate your options. Or read our clinical trial FAQ for answers to general questions.
Phone: 1-855-320-2092Online form: Request an appointment
Dana-Farber/Boston Children's is a teaching affiliate of Harvard Medical School.